JP2011505810A - ヒト化抗ヒトｃｄ３４抗体、その調製方法および使用 - Google Patents
ヒト化抗ヒトｃｄ３４抗体、その調製方法および使用 Download PDFInfo
- Publication number
- JP2011505810A JP2011505810A JP2010537235A JP2010537235A JP2011505810A JP 2011505810 A JP2011505810 A JP 2011505810A JP 2010537235 A JP2010537235 A JP 2010537235A JP 2010537235 A JP2010537235 A JP 2010537235A JP 2011505810 A JP2011505810 A JP 2011505810A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- human
- cells
- variable region
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 title claims abstract description 61
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 title claims abstract description 61
- 238000002360 preparation method Methods 0.000 title abstract description 14
- 239000011324 bead Substances 0.000 claims abstract description 47
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 18
- 210000001185 bone marrow Anatomy 0.000 claims abstract description 6
- 210000004027 cell Anatomy 0.000 claims description 97
- 239000002773 nucleotide Substances 0.000 claims description 24
- 125000003729 nucleotide group Chemical group 0.000 claims description 24
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 23
- 239000012634 fragment Substances 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 230000027455 binding Effects 0.000 claims description 16
- 210000000130 stem cell Anatomy 0.000 claims description 15
- 239000013604 expression vector Substances 0.000 claims description 14
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims description 8
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims description 8
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims description 7
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims description 7
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 3
- 229940127121 immunoconjugate Drugs 0.000 claims 2
- 230000001131 transforming effect Effects 0.000 claims 2
- 230000003525 myelopoietic effect Effects 0.000 claims 1
- 238000002054 transplantation Methods 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 6
- 208000014951 hematologic disease Diseases 0.000 abstract description 5
- 230000003211 malignant effect Effects 0.000 abstract description 5
- 239000000463 material Substances 0.000 abstract description 3
- OOIBFPKQHULHSQ-UHFFFAOYSA-N (3-hydroxy-1-adamantyl) 2-methylprop-2-enoate Chemical compound C1C(C2)CC3CC2(O)CC1(OC(=O)C(=C)C)C3 OOIBFPKQHULHSQ-UHFFFAOYSA-N 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 32
- 241000699666 Mus <mouse, genus> Species 0.000 description 25
- 239000002609 medium Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 15
- 239000000872 buffer Substances 0.000 description 14
- 239000013598 vector Substances 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 12
- 210000004700 fetal blood Anatomy 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 238000000246 agarose gel electrophoresis Methods 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 108091008146 restriction endonucleases Proteins 0.000 description 9
- 238000012163 sequencing technique Methods 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 7
- 239000002502 liposome Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 210000003995 blood forming stem cell Anatomy 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 239000012228 culture supernatant Substances 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 239000002122 magnetic nanoparticle Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 229940098773 bovine serum albumin Drugs 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 230000006957 competitive inhibition Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 238000003757 reverse transcription PCR Methods 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 201000000050 myeloid neoplasm Diseases 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 101100448444 Caenorhabditis elegans gsp-3 gene Proteins 0.000 description 3
- 102100022887 GTP-binding nuclear protein Ran Human genes 0.000 description 3
- 101000774835 Heteractis crispa PI-stichotoxin-Hcr2o Proteins 0.000 description 3
- 101000620756 Homo sapiens GTP-binding nuclear protein Ran Proteins 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 229920001213 Polysorbate 20 Polymers 0.000 description 3
- 101100393821 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GSP2 gene Proteins 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000003394 haemopoietic effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007885 magnetic separation Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 3
- 229920000136 polysorbate Polymers 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
- 101100283604 Caenorhabditis elegans pigk-1 gene Proteins 0.000 description 2
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 description 2
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 description 2
- 101001008255 Homo sapiens Immunoglobulin kappa variable 1D-8 Proteins 0.000 description 2
- 101001047628 Homo sapiens Immunoglobulin kappa variable 2-29 Proteins 0.000 description 2
- 101001008321 Homo sapiens Immunoglobulin kappa variable 2D-26 Proteins 0.000 description 2
- 101001047619 Homo sapiens Immunoglobulin kappa variable 3-20 Proteins 0.000 description 2
- 101001008263 Homo sapiens Immunoglobulin kappa variable 3D-15 Proteins 0.000 description 2
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 description 2
- 102100022949 Immunoglobulin kappa variable 2-29 Human genes 0.000 description 2
- 239000012901 Milli-Q water Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 108010084455 Zeocin Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 208000024908 graft versus host disease Diseases 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000007857 nested PCR Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- CWCMIVBLVUHDHK-ZSNHEYEWSA-N phleomycin D1 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC[C@@H](N=1)C=1SC=C(N=1)C(=O)NCCCCNC(N)=N)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C CWCMIVBLVUHDHK-ZSNHEYEWSA-N 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000013925 CD34 antigen Human genes 0.000 description 1
- 108050003733 CD34 antigen Proteins 0.000 description 1
- 235000021538 Chard Nutrition 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 102100034523 Histone H4 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 1
- 101001067880 Homo sapiens Histone H4 Proteins 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 206010025280 Lymphocytosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000003229 cytophilic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000007849 hot-start PCR Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 238000012900 molecular simulation Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000009738 saturating Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 230000010473 stable expression Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57426—Specifically defined cancers leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
- G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200710094456 CN101245108B (zh) | 2007-12-13 | 2007-12-13 | 抗人cd34抗体、其制备方法及用途 |
| CN200810043016 | 2008-01-08 | ||
| PCT/CN2008/001963 WO2009079922A1 (en) | 2007-12-13 | 2008-12-03 | Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011505810A true JP2011505810A (ja) | 2011-03-03 |
| JP2011505810A5 JP2011505810A5 (enExample) | 2012-01-26 |
Family
ID=40800709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010537235A Ceased JP2011505810A (ja) | 2007-12-13 | 2008-12-03 | ヒト化抗ヒトｃｄ３４抗体、その調製方法および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100311955A1 (enExample) |
| EP (1) | EP2233501B1 (enExample) |
| JP (1) | JP2011505810A (enExample) |
| BR (1) | BRPI0821211A2 (enExample) |
| CA (1) | CA2708407A1 (enExample) |
| WO (1) | WO2009079922A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2686418A4 (en) | 2011-03-17 | 2015-04-22 | Minerva Biotechnologies Corp | METHOD FOR THE PRODUCTION OF PLURIPOTENTAL STEM CELLS |
| US8785603B2 (en) | 2011-05-20 | 2014-07-22 | Siemens Healthcare Diagnostics Inc. | Antibodies to 25-hydroxyvitamin D2 and D3 and uses thereof |
| TWI443107B (zh) | 2011-12-29 | 2014-07-01 | Ind Tech Res Inst | 人源化之抗人類細胞表面抗原ｃｄ３４之單株抗體及其應用 |
| DK3105252T3 (da) | 2014-02-12 | 2019-10-14 | Michael Uhlin | Bispecifikke antistoffer til anvendelse ved stamcelletransplantation |
| US10604586B2 (en) * | 2016-05-09 | 2020-03-31 | Industrial Technology Research Institute | Humanized monoclonal antibody and uses thereof |
| CN109265547B (zh) * | 2018-07-23 | 2022-07-26 | 中国科学院微生物研究所 | 一种抗cd47抗体及其应用 |
| CN111879923A (zh) * | 2020-08-06 | 2020-11-03 | 深圳科隆生物新材料有限公司 | 一种可消除hama效应的试剂盒 |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| WO2025006799A1 (en) | 2023-06-27 | 2025-01-02 | Capstan Therapeutics, Inc. | Extracorporeal and ex vivo engineering of select cell populations from peripheral blood |
| CN116970650B (zh) * | 2023-09-22 | 2023-12-08 | 深圳华大生命科学研究院 | 一种包膜蛋白组合、含其的靶向病毒载体及制备方法 |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| CN118501458B (zh) * | 2024-05-08 | 2025-09-30 | 广东省第二人民医院（广东省卫生应急医院） | 一种外周血细胞外囊泡表面多种免疫标志物联合检测的试剂盒及方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11332578A (ja) * | 1998-05-25 | 1999-12-07 | Asahi Chem Ind Co Ltd | 細胞の分離装置及び分離方法 |
| JPH11332594A (ja) * | 1998-05-26 | 1999-12-07 | Asahi Chem Ind Co Ltd | Ｃｄ４陽性細胞の分離装置および分離方法 |
| US20070207210A1 (en) * | 2004-05-12 | 2007-09-06 | Brown Larry R | Protein Microspheres Retaining Pharmacokinetic and Pharmacodynamic Properties |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| CN1307640A (zh) * | 1998-05-25 | 2001-08-08 | 旭化成株式会社 | 细胞分离装置和分离方法 |
| ATE382633T1 (de) * | 2000-05-23 | 2008-01-15 | Baxter Healthcare Sa | Reagenzien zur zellselektion und verfahren zur anwendung |
| CN101245108B (zh) * | 2007-12-13 | 2013-04-10 | 上海抗体药物国家工程研究中心有限公司 | 抗人cd34抗体、其制备方法及用途 |
-
2008
- 2008-12-03 CA CA2708407A patent/CA2708407A1/en not_active Abandoned
- 2008-12-03 EP EP08865354A patent/EP2233501B1/en not_active Not-in-force
- 2008-12-03 BR BRPI0821211-2A patent/BRPI0821211A2/pt not_active IP Right Cessation
- 2008-12-03 WO PCT/CN2008/001963 patent/WO2009079922A1/zh not_active Ceased
- 2008-12-03 US US12/746,990 patent/US20100311955A1/en not_active Abandoned
- 2008-12-03 JP JP2010537235A patent/JP2011505810A/ja not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11332578A (ja) * | 1998-05-25 | 1999-12-07 | Asahi Chem Ind Co Ltd | 細胞の分離装置及び分離方法 |
| JPH11332594A (ja) * | 1998-05-26 | 1999-12-07 | Asahi Chem Ind Co Ltd | Ｃｄ４陽性細胞の分離装置および分離方法 |
| US20070207210A1 (en) * | 2004-05-12 | 2007-09-06 | Brown Larry R | Protein Microspheres Retaining Pharmacokinetic and Pharmacodynamic Properties |
Non-Patent Citations (3)
| Title |
|---|
| JPN6013045111; ＯＴＴＯ，Ｍ． ｅｔ ａｌ．: 'Ｓｅｌｅｃｔｉｏｎ ｏｆ ｓｔｅｍ ｃｅｌｌｓ ｂｙ ｕｓｉｎｇ ａｎｔｉｂｏｄｉｅｓ ｔｈａｔ ｔａｒｇｅｔ ｄｉｆｆｅｒｅｎｔ ＣＤ３４ ｅｐｉｔｏｐｅｓ ｙｉｅｌｄｓ ｄｉｆｆｅｒｅｎｔ ｐａｔ' Ｓｔｅｍ Ｃｅｌｌｓ Ｖｏｌ．２５， Ｎｏ．２, 200702, ｐｐ．５３７-４２ * |
| JPN6013045112; ＨＯＵ，Ｓ． ｅｔ ａｌ．: 'Ｈｕｍａｎｉｚａｔｉｏｎ ｏｆ ａｎ ａｎｔｉ-ＣＤ３４ ｍｏｎｏｃｌｏｎａｌ ａｎｔｉｂｏｄｙ ｂｙ ｃｏｍｐｌｅｍｅｎｔａｒｉｔｙ-ｄｅｔｅｒｍｉｎｉｎｇ ｒｅｇｉｏｎ ｇｒａｆｔｉｎｇ ｂａｓｅ' Ｊ． Ｂｉｏｃｈｅｍ． Ｖｏｌ．１４４， Ｎｏ．１, 200807, ｐｐ．１１５-２０ * |
| JPN6013045114; ＱＩＡＮ，Ｗ． ｅｔ ａｌ．: 'Ｄｅｖｅｌｏｐｍｅｎｔ ｏｆ ｎｅｗ ｖｅｒｓｉｏｎｓ ｏｆ ａｎｔｉ-ｈｕｍａｎ ＣＤ３４ ｍｏｎｏｃｌｏｎａｌ ａｎｔｉｂｏｄｉｅｓ ｗｉｔｈ ｐｏｔｅｎｔｉａｌｌｙ ｒｅｄｕｃｅｄ ｉｍｍｕｎｏ' Ｂｉｏｃｈｅｍ． Ｂｉｏｐｈｙｓ． Ｒｅｓ． Ｃｏｍｍｕｎ． Ｖｏｌ．３６７， Ｎｏ．２, 20080307, ｐｐ．４９７-５０２ * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2233501A4 (en) | 2010-12-01 |
| EP2233501B1 (en) | 2012-07-11 |
| BRPI0821211A2 (pt) | 2015-06-16 |
| WO2009079922A1 (en) | 2009-07-02 |
| EP2233501A1 (en) | 2010-09-29 |
| CA2708407A1 (en) | 2009-07-02 |
| US20100311955A1 (en) | 2010-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2233501B1 (en) | Humanized anti-cd34 monoclonal antibody, the preparation and uses thereof | |
| CN107955071B (zh) | 人源抗人cd47抗体及其编码基因与应用 | |
| CN107880128B (zh) | 一种抗cd19的全人源抗体或抗体片段及其方法和应用 | |
| JP7262597B2 (ja) | 二重特異性抗体及びその作製方法と使用 | |
| CN110526971A (zh) | 抗-CD38抗体和与致弱干扰素α-2B的融合体 | |
| SA112330278B1 (ar) | مواد ضابطة جديدة وطرق للاستخدام | |
| CN111349163B (zh) | 针对cd123的单克隆抗体 | |
| CN108164600B (zh) | 一种抗gpc3抗体及其制备方法和用途 | |
| CN113383017A (zh) | 新型双特异性抗体分子以及同时结合pd-l1和lag-3的双特异性抗体 | |
| JP7512413B2 (ja) | 抗ｐｄ－ｌ１およびｐｄ－ｌ２抗体ならびにその誘導体および用途 | |
| EP4458853A1 (en) | Development of novel upar single-domain antibody | |
| WO2022247804A1 (zh) | 抗gprc5d抗体、其制备方法与用途 | |
| WO2023125888A1 (zh) | 一种gprc5d抗体及其应用 | |
| CN116848147A (zh) | Cd19人源化抗体及其应用 | |
| TW202346356A (zh) | 抗cd3抗體、其製備方法及應用 | |
| CN113912728B (zh) | 降低抗人白介素-33单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法 | |
| CN117209608A (zh) | 一种靶向cd47的抗体及其应用 | |
| WO2024017326A1 (zh) | 抗gprc5d纳米抗体及其应用 | |
| CN118420758A (zh) | 人源化的结合cd19的抗体或cd19抗原结合片段及应用 | |
| CN114478770A (zh) | 抗体及其制备方法 | |
| CN114075285A (zh) | 抗人cd38人源化单克隆抗体及其应用 | |
| CN101481417A (zh) | 抗人cd34人源化抗体、其制备方法及用途 | |
| CN114316047B (zh) | 一组pd-1单克隆抗体及其医药用途 | |
| CN114075284B (zh) | Cd47结合分子及其用途 | |
| CN111704668B (zh) | 抗ccr4抗体及其在治疗癌症中的应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111201 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111201 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130910 |
|
| A045 | Written measure of dismissal of application [lapsed due to lack of payment] |
Free format text: JAPANESE INTERMEDIATE CODE: A045 Effective date: 20140128 |